HIVMicrobiome
Meeting category
Date(s)
19 Oct 2021 - 21 Oct 2021
Meeting type
Virtual Meeting
Organizer

International Workshop on Microbiome and HIV Pathogenesis, Prevention, and Treatment 2021

Related Enduring Materials

Enduring Materials

Download the Program & Abstract Book

The presentation videos and slides for speakers’ lectures are made available, provided that they have granted us permission to do so

Final Program

Day 1 - Tuesday, 19 October 2021

Opening Session - 11:05
11:05 EDT
Introduction to the Microbiome for HIV Clinicians and Researchers
Catherine Lozupone, PhD
University of Colorado, United States
Session 1: Prevention - 11:30
11:30 EDT
Evidence for Sexual Transmission of Bacterial Vaginosis
Catriona Bradshaw, Professor, MD, FAChSHM, PhD
Melbourne Sexual Health Centre, Alfred Hospital and Central Clinical School, Monash University, Australia
11:45 EDT
Geo-Adapted Live Biotherapeutic Strategies for HIV Prevention
Jo-Ann Passmore, PhD
University of Cape Town, South Africa
12:00 EDT
Immunomodulatory Properties of Cervicovaginal Lactobacillus Isolates Are Associated with Lactic Acid Production and Bacterial Proteome Profiles (#1)
Monalisa Manhanzva
South Africa
12:07 EDT
Transkingdom Connections in the Female Reproductive Tract in Health and Bacterial Vaginosis (#2)
Ferralita Madere
United States
Session 2: Transmission - 12:40
12:40 EDT
Vaginal Lactobacillus-Derived Extracellular Vesicles in Protecting from HIV-1 Transmission
12:55 EDT
Penile Anaerobic Bacteria as a Risk Factor for HIV Infection
Cindy Liu, MD, MPH, PhD
George Washington University, United States
13:10 EDT
HIV Replication, Transmission, and the Metabolome of the Female Reproductive Tract (#4)
Kaitlin Marquis
United States
Session 3: Vaccines - 13:45
13:45 EDT
Gut Microbiota During Early Life Modulates Vaccine Immunogenicity in Infants Exposed to HIV
Heather Jaspan, MD, PhD
Seattle Children’s Research Institute, United States; University of Cape Town, South Africa
14:00 EDT
Exploring the Role of the Microbiome on HIV Infection in Humanized Mice
Angela Wahl, PhD
University of North Carolina at Chapel Hill, United States
14:15 EDT
Rational Donor Fecal Microbiota Transplantation in HIV (Refresh Study): Preliminary Results of Shotgun Sequencing Analysis (#5)
Alba Talavera Rodríguez
Spain
14:20 EDT
Gut Microbiome and Immune Phenotype Response to Art/Co-trimoxazole Treatment Differs among Plwh of Rural versus Urban Zimbabwe: A Multicenter Longitudinal Interventional Study (#6)
Alessandro Lazzaro
Italy

Day 2 - Wednesday, 20 October 2021

Opening Session - 11:05
11:05 EDT
Microbiome and the Aging Brain: Moving Toward Mechanism
John F. Cryan, B.Sc. (Hons), PhD
University College Cork, Ireland
Session 4: Treatment - 11:30
11:30 EDT
Metabolome-Microbiome Crosstalk Towards Natural Immune Control in HIV
Ujjwal Neogi, MSc, PhD
Karolinska Institute, Sweden
11:45 EDT
Isolation and Proteomic Profiling of Translocating Bacteria in Progressive SIV Infection of Rhesus Macaques (#7)
Jacob Flynn
United States
11:52 EDT
Butyrate Administration Does Not Improve Immune Reconstitution in Antiretroviral-Treated Siv-Infected Macaques (#8)
Alexandra Ortiz
United States
Session 5: Comorbidities - 12:25
12:25 EDT
Microbiome, Diabetes, and HIV Inflammation
Jean-Pierre Routy, MD, FRCPC
McGill University Health Centre, Canada
12:40 EDT
HIV, HPV and the Microbiome: Partners in Crime?
Sergio Serrano-Villar, MD, PhD
University Hospital Ramón y Cajal, Spain
12:55 EDT
Age-Associated Gut Dysbiosis, Marked by Loss of Butyrogenic Potential, Correlates with Altered Plasma Neuroactive Tryptophan Metabolites in Older People Living with HIV (#9)
Smita Ghare
United States
13:00 EDT
Interactions among Mycobiome, Bacteriome, Inflammation and Diet in HIV Infection (#10)
Maria Jose Gosalbes
Spain
Guided Posters Tour - 13:45
13:45 EDT
HIV-1 infection and Gut Microbiome (#1)
Jyotsna Jaiswal
India
13:48 EDT
Longitudinal Analysis of the Lung Microbiome in an Immune-Compromised Patient Population (#2)
Samantha Whiteside
United States
13:51 EDT
Peptidoglycans from Enteric Bacteria Differentially Induce Epithelial Cell Activation (#3)
Charles Neff
United States
13:55 EDT
Factors Related to Composition of a More Western versus Agrarian Diet in HIV-Infected Individuals in Zimbabwe (#4)
Nichole Nusbacher
United States

Day 3 - Thursday, 21 October 2021

Opening Session - 11:05
11:05 EDT
The Gut Microbiome in Health and Disease States: Challenges and Opportunities for Developing Microbiome-based Diagnostics and Interventions in the Era of Precision Medicine
Eugene B. Chang, MD
University of Chicago, United States
Session 6: Pathogenesis - 11:30
11:30 EDT
High Resolution Metagenomic Analysis of the Human Microbiome
Nicola Segata, PhD
University of Trento, Italy
11:45 EDT
Microbiome and HIV: A Clinical Perspective
Irini Sereti, MD
NIAID/NIH, United States
12:00 EDT
Lung Microbiome in Highly Immunosuppressed Lung Transplant Recipients Drives Inflammation and Primary Graft Dysfunction (#11)
John McGinniss
United States
12:07 EDT
Gut Microbiome Signatures Linked to HIV-1 Reservoir Size and Viremia Control (#12)
Alessandra Borgognone
Spain
Session 7: COVID-19 and Microbiome - 12:40
12:40 EDT
Lower Airway Microbiome in Critically Ill COVID-19 Patients
Leopoldo Segal, MD
NYU Grossman School of Medicine, United States
12:55 EDT
Signatures of COVID-19 Severity and Immune Response in the Respiratory Tract Microbiome
Ronald Collman, MD
University of Pennsylvania, Perelman School of Medicine, United States
13:10 EDT
SARS-CoV-2 Infection Associated with Microbial Translocation Across Intestinal Mucosa (#13)
Kelsie Brooks
United States
13:17 EDT
Inflammation and Pulmonary Dysfunction Associated with Elevated Sars-Cov-2-Specific T Cells in Post-acute Sequelae COVID-19 (#14)
Katherine Littlefield
United States
Overview
Image
Microbiome
About this Program

The 7th edition of the International Workshop on Microbiome and HIV Pathogenesis, Prevention, and Treatment 2021 successfully took place from 19 - 21 October 2021 in a virtual format.

The interplay between human gut microbiota and the immune response is an integral component of many physiological processes, but also pathological conditions. Therefore, understanding the microbiome-immunity crosstalk is central in order to illuminate molecular mechanisms that maintain hemostasis in health, but also to decipher what goes wrong in a disease.

This rapidly evolving research area may offer a comprehensive understanding on the interplay between the HIV infection and the host immunity, and how it contributes to an altered immune status and disease pathogenesis. This ultimately may lead to the identification of novel drug targets with a distinct mode of action compared to currently available therapies. Whereas research in this area may be presented at major conferences, there is often limited time for in-depth discussion and debate among cross-disciplinary experts on the new data and their implications.

This 3-day workshop had invited lectures by key opinion leaders, oral abstract presentations, and poster presentations. This data contributed to translating research achievements into opportunities for the development of preventive approaches to reduce virus transmission and to provide a better understanding of the impact of the microbiome on host immunity.

Clinicians and researchers with an interest in Microbiome and HIV Pathogenesis, Prevention, and Treatment are most welcome to attend this workshop.

Thanks for joining us at Microbiome & HIV 2021!

Program Chairs 2021

General Information 

Unique Features
The unique features for the workshop include its multidisciplinary nature and significance in enabling participants to learn how the host microbiome can influence responses to our current HIV therapies and to further our ability to develop novel prevention and therapeutic strategies for HIV that will lead to the reduction of new HIV infections and the burden of non-communicable diseases in individuals living with HIV.

This workshop is unique in its approach, as it engages basic scientists and clinicians from the HIV field, leading scientists involved in microbiome research including bioinformatics experts, as well as clinicians and researchers with an interest in microbiome in HIV pathogenesis, prevention, and treatment.
Who Should Attend?
Clinicians and researchers with an interest in Microbiome in general and Pathogenesis in relation to HIV.
Meeting Objectives
This meeting aims to:

- Gather cross-disciplinary professionals in the field of microbiome research to provide a better understanding of the impact of the microbiome on host immunity; and

- Develop a better understanding of how the microbiome affects the pathogenesis of HIV across mucosal sites.
Learning Objectives
After participating in this workshop, participants will be able to:

-Increase understanding of the complex interplay between the human microbiome, host immunity, and HIV pathogenesis;

-Implement gained knowledge in development of novel targets and strategies for HIV prevention and treatment;

-Reflect on the host and microbial factors that affect HIV susceptibility, and transmission;

-Identify host and microbial factors that contribute to the onset of HIV-associated comorbidities;

-Comprehend interplay between the human microbiome, host immunity, and SARS-COV-2 infection.

Practical Information 

Certificate of Attendance
A digital certificate of attendance will be sent to participants upon completion of the post-meeting survey
Language
The official language of the workshop is English. No simultaneous translation will be provided.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Video Recordings
All presentations that we were granted permission for will be posted on the workshop website as soon as possible after the workshop is finished, provided that the speaker has given permission to do so.
Committees
Meeting Chairs
Organizing Committee

The members of the Organizing Committee (OC) discuss, on a frequent basis, the scientific program of the workshop, identify interesting topics and candidate speakers.

Scientific Committee

The members of the Scientific Committee assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

  • Shaun Barnabas, MD - University of Cape Town, South Africa

  • Stacy Carrington-Lawrence, PhD - NIH/OAR, USA

  • Que Dang, PhD - NIAID/NIH, USA

  • Wendy Henderson, PhD, MSN, CRNP, FAAN - NINR, NIH, DHHS, USA

  • Steve Innes, MBChB, MRCPCH, MPhil, PhD - Stellenbosch University, South Africa

  • Douglas Kwon, MD, PhD - Ragon Institute of MGH, MIT and Harvard, USA

  • Angela Malaspina, PhD - NIAID/NIH, USA

  • John McGowan, PhD - NIAID, USA

  • Piotr Nowak, MD, PhD - Karolinska University Hospital, Sweden

  • Sandra Pinto Cardoso, PhD - Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico

  • Angela Wahl, PhD - University of North Carolina at Chapel Hill, USA

  • Cara Wilson, MD - University of Colorado, USA

Support
Friend Level Support
Independent Medical Education Grant

Supporter

MSD has provided part funding for this Independent Medical Education program.

MSD has had no input into selection of speakers or the content of the materials and presentations.

Support Our Initiative
Financial backing helps us deliver an impactful meeting experience to the benefit of healthcare professionals involved in microbiome and HIV.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
 
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Ms. Federica Ressa at federica@amededu.com or call +31 30 230 7140.

 
Benefits of Support
By supporting this program, we can offer the following advantages for your company. *Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Non-commercial interviews with company representatives
  • Verbal acknowledgment during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
  • Digital and printed advertising opportunities 
  • Social media shout-outs


 
*Subject to the support level.

Endorsers
Language
Sorry… This form is closed to new submissions.